Cargando…

Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis

BACKGROUND: Conversion therapy provides selected patients with unresectable hepatocellular carcinoma the opportunity to undergo a curative hepatectomy and achieve long-term survival. Although various regimens have been used for conversion therapy, their conversion rate and safety remain uncertain. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pei, Yinxuan, Li, Weiwei, Wang, Zixiang, Liu, Jinlong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513549/ https://www.ncbi.nlm.nih.gov/pubmed/36176393 http://dx.doi.org/10.3389/fonc.2022.978823

Ejemplares similares

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Li, Weiwei, et al.
Publicado: (2022)

Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis
por: Wang, Zixiang, et al.
Publicado: (2022)

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021)

Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma
por: Chen, Kang, et al.
Publicado: (2022)

Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis
por: Liao, Zheng, et al.
Publicado: (2023)

Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis
por: Chen, Xinyu, et al.
Publicado: (2021)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
por: Li, Xingzhi, et al.
Publicado: (2023)

Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization
por: He, Chengjian, et al.
Publicado: (2022)

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
por: Yi, Yong, et al.
Publicado: (2022)

First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
por: Liu, Wenfeng, et al.
Publicado: (2021)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials
por: Dong, Han, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices
por: Tao, Ziwen, et al.
Publicado: (2021)

Pharmacogenetics – Getting Closer
por: MacDonald, Ian M
Publicado: (2009)

Getting closer to the clinic
por: Tanaka, Toshiko, et al.
Publicado: (2022)

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2023)

Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
por: Nabrinsky, Edward, et al.
Publicado: (2020)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
por: Xu, Ying, et al.
Publicado: (2022)

Brazil and CERN get closer
Publicado: (2002)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis
por: Long, Jiaye, et al.
Publicado: (2023)

Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation
por: Wei, Jialiang, et al.
Publicado: (2020)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
por: Shao, Wenbo, et al.
Publicado: (2019)

Case report and literature review: Conversion surgery for initially unresectable huge retroperitoneal liposarcoma after preoperative radiotherapy
por: Cheng, Sarah Hsin, et al.
Publicado: (2023)

Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes
por: Sayan, Mutlay, et al.
Publicado: (2019)

Getting Closer to a Vaccine for Hookworm
Publicado: (2005)

Getting the public closer to the experimental facilities
por: Pereira Peixoto, Ana Paula, et al.
Publicado: (2020)

Finding smORFs: getting closer
por: Couso, Juan Pablo
Publicado: (2015)

Claudins get a closer look
por: Sedwick, Caitlin
Publicado: (2018)

Improving the good to get closer to the perfect
por: Idrovo, Alvaro J
Publicado: (2021)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
por: Xia, Wei-Li, et al.
Publicado: (2022)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study
por: Zhang, Jinliang, et al.
Publicado: (2021)

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
por: Wu, Jia-Lin, et al.
Publicado: (2023)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0m9i51iaunp4sdqkhb6sd88ec9